Affordable Access

deepdyve-link
Publisher Website

Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience.

Authors
  • Loprinzi, Charles L
  • Barton, Debra L
  • Sloan, Jeff A
  • Novotny, Paul J
  • Dakhil, Shaker R
  • Verdirame, Joseph D
  • Knutson, Wilma H
  • Kelaghan, Joseph
  • Christensen, Brad
Type
Published Article
Journal
Menopause The Journal of The North American Menopause Society
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Jan 01, 2008
Volume
15
Issue
4 Pt 1
Pages
655–660
Identifiers
DOI: 10.1097/gme.0b013e3181679150
PMID: 18427355
Source
Medline
License
Unknown

Abstract

Data from the pilot trials have given direction for substances that ought to be further explored in more definitive studies. In men, randomized studies demonstrate that hot flashes are markedly decreased by low doses of megestrol acetate, moderately decreased by gabapentin, but not substantially decreased by clonidine. Results from the randomized trials in women demonstrate that hot flashes are markedly decreased by relatively low doses of progestational agents (megestrol acetate and medroxyprogesterone acetate), moderately decreased by venlafaxine, mildly to moderately decreased by fluoxetine, mildly decreased by clonidine, but not substantially decreased by vitamin E, a soy phytoestrogen product, or black cohosh. Last, the data investigated in these studies support the hypothesis that, for the treatment of hot flashes in women, the results of therapeutic maneuvers are similar regardless of whether the patient has a history of breast cancer and/or is taking tamoxifen.

Report this publication

Statistics

Seen <100 times